Drugs / AGN-207281
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01215786 | Oct → Dec 2010 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-207281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215786 ↗ |
| Route | Other | “AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes” NCT01215786 ↗ |